CorMedix Inc - Asset Resilience Ratio
CorMedix Inc (CRMD) has an Asset Resilience Ratio of 0.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how CorMedix Inc's Asset Resilience Ratio has changed over time. Check CorMedix Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CorMedix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of CorMedix Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.69 Million | 0.45% |
| Total Liquid Assets | $3.69 Million | 0.45% |
Asset Resilience Insights
- Limited Liquidity: CorMedix Inc maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CorMedix Inc Industry Peers by Asset Resilience Ratio
Compare CorMedix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for CorMedix Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for CorMedix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.45% | $3.69 Million | $826.14 Million | -8.84pp |
| 2024-12-31 | 9.29% | $11.04 Million | $118.85 Million | -30.18pp |
| 2023-12-31 | 39.47% | $32.39 Million | $82.06 Million | +14.25pp |
| 2022-12-31 | 25.22% | $15.64 Million | $62.04 Million | +7.60pp |
| 2021-12-31 | 17.62% | $12.15 Million | $68.95 Million | +8.61pp |
| 2020-12-31 | 9.01% | $4.44 Million | $49.31 Million | -31.64pp |
| 2019-12-31 | 40.66% | $11.98 Million | $29.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $18.83 Million | -- |
| 2017-12-31 | 11.92% | $1.60 Million | $13.45 Million | -43.32pp |
| 2016-12-31 | 55.24% | $12.10 Million | $21.91 Million | -8.28pp |
| 2015-12-31 | 63.52% | $23.57 Million | $37.10 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $5.10 Million | -- |
| 2013-12-31 | 7.45% | $221.00K | $2.97 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.15 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.56 Million | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more